Cargando…
Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target
Pirfenidone (PFD), a pyridone compound, is well recognized as an antifibrotic agent tailored for the treatment of idiopathic pulmonary fibrosis. Recently, through its anti-inflammatory and anti-oxidant effects, PFD based clinical trial has also been launched for the treatment of coronavirus disease...
Autores principales: | Chang, Wei-Ting, Ragazzi, Eugenio, Liu, Ping-Yen, Wu, Sheng-Nan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276140/ https://www.ncbi.nlm.nih.gov/pubmed/32525005 http://dx.doi.org/10.1016/j.ejphar.2020.173237 |
Ejemplares similares
-
Antifibrotic Effects of Caffeine, Curcumin and Pirfenidone in Primary Human Keratocytes
por: Talpan, Delia, et al.
Publicado: (2023) -
Design, Synthesis and Antifibrotic Activities of Carbohydrate- Modified 1-(Substituted aryl)-5-trifluoromethyl-2(1H) Pyridones
por: Lou, Qinghua, et al.
Publicado: (2012) -
Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis
por: Komiya, Chikara, et al.
Publicado: (2017) -
The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro
por: Stougaard, Julie, et al.
Publicado: (2018) -
Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
por: Vu, Tuong N., et al.
Publicado: (2019)